Valuation: Endonovo Therapeutics Inc

Market Cap 27.73L 24.36L 22.65L 20.79L 39.05L 27Cr 39.66L 2.69Cr 1.05Cr 13Cr 1.04Cr 1.02Cr 45Cr P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 99.26L 87.18L 81.08L 74.4L 1.4Cr 96Cr 1.42Cr 9.63Cr 3.76Cr 47Cr 3.73Cr 3.65Cr 162.49Cr EV / Sales 2021
11,24,21,804x
EV / Sales 2022 7,86,89,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 77 30/11/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%+6.79%+57.25%+71.56% 5.73TCr
-1.92%+6.03%+40.64%+80.66% 5.5TCr
-0.46%-1.29%+2.86%+425.15% 2.32TCr
-2.97%-2.35%-22.53%-15.34% 2.26TCr
-1.13%+1.05%+20.81%-7.73% 2.05TCr
+0.40%+2.22%+26.08%-29.81% 1.76TCr
-0.10%+1.88%+34.42%+545.91% 1.57TCr
-1.30%-5.02%+170.77%+310.94% 1.45TCr
-0.50%-0.98%+21.43%+179.36% 1.39TCr
Average -0.88%+1.28%+39.08%+173.41% 2.67TCr
Weighted average by Cap. -0.93%+2.10%+38.58%+137.05%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 7.04 0.1 0.71 0.28 3.46 0.27 0.27 11.97 0.14 0.12 0.11 0.1 0.19 13.03 0.19 1.31 0.51 6.41 0.51 0.5 22.16
Net income -31.05L -27.27L -25.36L -23.27L -43.73L -30Cr -44.4L -3.01Cr -1.18Cr -15Cr -1.17Cr -1.14Cr -51Cr -1.85Cr -1.62Cr -1.51Cr -1.38Cr -2.6Cr -177.91Cr -2.64Cr -18Cr -7Cr -87Cr -6.94Cr -6.79Cr -302.43Cr
Net Debt 70.95L 62.32L 57.95L 53.18L 99.92L 68Cr 1.01Cr 6.88Cr 2.69Cr 34Cr 2.66Cr 2.61Cr 116.15Cr 71.53L 62.83L 58.43L 53.61L 1.01Cr 69Cr 1.02Cr 6.94Cr 2.71Cr 34Cr 2.69Cr 2.63Cr 117.09Cr
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-